A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- María Vidal (ORCID: https://orcid.org/0000-0003-1992-5727)
- François‐Clément Bidard (ORCID: https://orcid.org/0000-0001-5932-8949)
- Patrick Neven (ORCID: https://orcid.org/0000-0002-1434-9460)
- Peter A. Kaufman (ORCID: https://orcid.org/0000-0003-3677-6807)
- Roohi Ismail‐Khan (ORCID: https://orcid.org/0000-0002-1301-6736)
- Bastien Nguyen (ORCID: https://orcid.org/0000-0002-6166-4746)
- Kelly K. Hunt (ORCID: https://orcid.org/0000-0001-9156-8723)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Manali Bhave (ORCID: https://orcid.org/0000-0003-4020-5871)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Duncan Wheatley (ORCID: https://orcid.org/0000-0002-1919-5114)
- Nicole Stahl
- Umut Özbek (ORCID: https://orcid.org/0000-0002-9034-7416)
- Shawn T. Estrem
- Rebecca Aft (ORCID: https://orcid.org/0000-0001-8569-7131)
- Claudia Karacsonyi
- Peter Schmid (ORCID: https://orcid.org/0000-0001-9817-5228)
- Eunice Yuen (ORCID: https://orcid.org/0000-0003-2145-6368)
- Eva Ciruelos (ORCID: https://orcid.org/0000-0002-2796-1042)
- Philippe Aftimos (ORCID: https://orcid.org/0000-0001-9946-4726)
- Swati Kulkarni (ORCID: https://orcid.org/0000-0002-4213-0933)
- Miguel Martín (ORCID: https://orcid.org/0000-0001-9237-3231)
- Stacey Carter (ORCID: https://orcid.org/0009-0005-1735-0431)
- Vanessa Rodrik-Outmezguine
Institutions
- University of Vermont (US)
- Northwestern University (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- Queen Mary University of London (GB)
- Eli Lilly (United States) (US)
- Baylor College of Medicine (US)
- Breast Cancer Research Foundation (US)
- Washington University in St. Louis (US)
- Royal Cornwall Hospital Trust (GB)
- Royal Cornwall Hospital (GB)
- Universitair Ziekenhuis Leuven (BE)
- Institut Jules Bordet (BE)
- Hospital General Universitario Gregorio Marañón (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Piedmont Cancer Institute (US)
- Sarah Cannon (US)
- Helios Hospital Schwerin (DE)
- Hospital Universitario 12 De Octubre (ES)
- HM Hospitales (ES)
- Tennessee Oncology (US)
- Vermont Cancer Support Network (US)
- Comprehensive Cancer Center Erlangen (DE)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- GEICAM – Spanish Breast Cancer Group (ES)
- Universitat de Barcelona (ES)
- Institut Curie (FR)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2113
- Citations
- 6
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Eli Lilly and Company